{
    "clinical_study": {
        "@rank": "124529", 
        "acronym": "HATFF", 
        "arm_group": [
            {
                "arm_group_label": "Glyoxalase 1 inducer", 
                "arm_group_type": "Active Comparator", 
                "description": "Glyoxalase 1 inducers (2), capsule, 90 mg & 120 mg, once daily, 10 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, capsule, once daily, 10 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether dietary inducers of glyoxalase 1 are\n      effective in improving metabolic and vascular health."
        }, 
        "brief_title": "Healthy Aging Through Functional Food", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glucose Intolerance", 
            "Aortic Stiffness", 
            "Vasodilation"
        ], 
        "condition_browse": {
            "mesh_term": "Glucose Intolerance"
        }, 
        "detailed_description": {
            "textblock": "The aim of the study is to evaluate dietary inducers of glyoxalase 1 for effects on\n      metabolic and vascular health in overweight volunteers at risk of developing type 2\n      diabetes. The research objectives are:\n\n      (i) To evaluate dietary inducers of glyoxalase 1 for effects on markers of glucose\n      metabolism during an oral glucose tolerance test (oGTT), (ii) To evaluate dietary inducers\n      of glyoxalase 1 for effects on vascular function on three levels, using finger fold\n      capillary density by capillaroscopy (FFCD), arterial stiffness by aortal pulse wave velocity\n      (aPWV) and flow mediated dilatation (FMD); and effects on metabolic and pro-inflammatory\n      markers in circulating blood and urine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI 25 - 40 kg/m2 (>23 kg/m2 for Asians), with normal, impaired fasting or impaired\n             postprandial glucose.\n\n          -  No other relevant morbidities.\n\n          -  Women will be preferably post-menopausal.\n\n        Exclusion Criteria:\n\n          -  Severe hypertriglyceridemia.\n\n          -  Uncontrolled hypertension, cardiovascular disease, relevant renal or hepatic disease,\n             diabetes, and other relevant morbidity.\n\n          -  Excess alcohol consumption, smoking, acute pharmacological treatment with drugs\n             affecting glucose metabolism such as steroids and antibiotics.\n\n          -  Anticoagulants.\n\n          -  Intake of herbal remedies.\n\n          -  Food allergies."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095873", 
            "org_study_id": "PJT_HATFF", 
            "secondary_id": "TSB101129"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Glyoxalase 1 inducer", 
                    "Placebo"
                ], 
                "description": "Dietary bioactive", 
                "intervention_name": "Glyoxalase 1 inducer", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Glyoxalase 1 inducer dietary bioactive 1", 
                    "Glyoxalase 1 inducer dietary bioactive 2"
                ]
            }, 
            {
                "arm_group_label": [
                    "Glyoxalase 1 inducer", 
                    "Placebo"
                ], 
                "description": "Mannitol, 210 mg", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oral glucose tolerance test", 
            "Flow mediated dilatation", 
            "Aortal pulse wave velocity", 
            "Finger-fold capillary density by capillaroscopy"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "S.A.Qureshi@warwick.ac.uk", 
                "last_name": "Sheharyar Qureshi, MBBS, MRCP", 
                "phone": "07801435928"
            }, 
            "contact_backup": {
                "email": "Martin.Weickert@uhcw.nhs.uk", 
                "last_name": "Martin O Weickert, MD", 
                "phone": "02476 965971"
            }, 
            "facility": {
                "address": {
                    "city": "Coventry", 
                    "country": "United Kingdom", 
                    "state": "Warwickshire", 
                    "zip": "CV22DX"
                }, 
                "name": "University Hospitals Coventry & Warwickshire NHS Trust (UHCW)"
            }, 
            "investigator": [
                {
                    "last_name": "Martin O Weickert, MD FRCP", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sheharyar Qureshi, MBBS MRCP", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.", 
        "other_outcome": [
            {
                "description": "Aortal pulse wave velocity is measured by a non-invasive oscillometric device.", 
                "measure": "Change in aortal pulse wave velocity (aPWV)", 
                "safety_issue": "No", 
                "time_frame": "0, 10, 16 and 26 weeks"
            }, 
            {
                "description": "Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed.  Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion.", 
                "measure": "Change in flow-mediated dilatation (FMD)", 
                "safety_issue": "No", 
                "time_frame": "0, 10, 16 and 26 weeks"
            }
        ], 
        "overall_contact": {
            "email": "S.A.Qureshi@warwick.ac.uk", 
            "last_name": "Sheharyar Qureshi, MBBS, MRCP", 
            "phone": "07801435928"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Warwick", 
                "last_name": "Paul J Thornalley, BSc PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospitals Coventry & Warwickshire NHS Trust", 
                "last_name": "Martin O Weickert, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: Research Councils UK", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (> 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling.", 
            "measure": "Change in oral glucose tolerance test (oGGT)", 
            "safety_issue": "No", 
            "time_frame": "Weeks 0, 10, 16 and 26"
        }, 
        "reference": {
            "PMID": "22188542", 
            "citation": "Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, Park BK, Souma T, Moriguchi T, Yamamoto M, Thornalley PJ. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J. 2012 Apr 1;443(1):213-22. doi: 10.1042/BJ20111648."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095873"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Warwick", 
            "investigator_full_name": "Professor Paul J. Thornalley", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements.", 
            "measure": "Change in finger-fold capillary density by capillaroscopy", 
            "safety_issue": "No", 
            "time_frame": "0, 10, 16 and 26 weeks"
        }, 
        "source": "University of Warwick", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Technology Strategy Board (UK)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Unilever R&D", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Warwick", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}